Company
Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

Interdisciplinary Team

Deep Genomics has over 50 team members, with expertise in artificial intelligence, automation, cell and molecular biology, clinical development, in vitro disease models, machine learning, medicine, molecular genetics, preclinical development, organic chemistry, and software engineering.

Management Team

Brendan Frey, Ph.D.

Founder and Chief Executive Officer

Ferd Massari, M.D.

Chief Medical Officer

Amanda Kay, Ph.D.

Chief Business Officer

Amit Deshwar, Ph.D.

Head of Predictive Systems

Jeffrey Brown, Ph.D.

VP and Head of Preclinical Research

Matt Cahill, J.D., Ph.D., M.B.A.

Vice President of Business Operations & Finance

Hyla Pollak

Vice President of People Operations

Daniele Merico, Ph.D.

Head of Target Identification

Troy Simpson

Head of Research Operations

Brendan Frey, Ph.D.

Brendan Frey is an internationally acclaimed entrepreneur, engineer and scientist. He is Founder, CEO and Chief Engineer of Deep Genomics and he co-founded the Vector Institute for Artificial Intelligence. Brendan made fundamental contributions in the fields of deep learning, genomic medicine, and information technology. He co-authored over 200 papers in these areas, including over a dozen that appeared in Nature, Science and Cell and were on multiple occasions highlighted on the front covers of those magazines. His work with Geoffrey Hinton on the 'wake-sleep algorithm' helped to launch the field of deep learning (Science 1995). His work on deep learning and on factor graphs forms the foundation of thousands of products used world-wide; for example, the WiFi telecommunications standard is based on an algorithm that Brendan co-invented.

Brendan was a pioneer in developing AI systems that could accurately predict normal and pathological cell and genome biology, facilitating biomedical breakthroughs. This work led to the discovery of new biology, the founding of Deep Genomics in 2015, the first AI system for predicting pathogenic mutations and identifying therapeutic targets, and the development of new therapeutic candidates for patients with genetic disorders. 

Brendan is Professor of Engineering and Medicine at the University of Toronto and is a Fellow of the American Association for the Advancement of Science, a Fellow of the Institute of Electrical and Electronic Engineers, a Senior Fellow of the Canadian Institute for Advanced Research, and a Fellow of the Royal Society of Canada. Brendan has advised the leadership of Microsoft Research on machine learning and deep learning technology, and he was a member of its Technical Advisory Board. He has held numerous researcher and professor positions at the University of Illinois at Urbana-Champaign, Cambridge University in England, the Isaac Newton Institute for Mathematical Sciences and the University of Waterloo.

Brendan received his PhD from the University of Toronto in 1997.

Ferd Massari, M.D.

Dr. Massari comes to Deep Genomics with decades of experience in the pharmaceutical and biotech industries. Located in Boston, Massachusetts, Ferd is responsible for all development activities including non-clinical toxicology, chemistry manufacturing controls, translational medicine and clinical trials. 

Prior to Deep Genomic, he served as VP and Global Head of Clinical and Medical Affairs in the rare diseases division of Shire, Vice President of Worldwide Medical Affairs at Pfizer, Vice President of Clinical Research at Pharmacia, and began his career at Merck Research Laboratories. Dr. Massari has led teams that have developed groundbreaking treatments for rare diseases, resistant bacterial infections and HIV infection among others. Most recently, he helped to found Kintai Therapeutics (now Senda Biosciences) out of Flagship Pioneering, building a team of over 60 researchers in computational biology, metabolomics, medicinal chemistry and other disciplines leading to six preclinical programs in three years.

Dr. Massari trained in internal medicine after obtaining his medical degree at Jefferson Medical College in Philadelphia under a NHSC scholarship. He received his Allergy and Immunology training at the U.S. NIAID in the laboratory of Dr. Anthony S. Fauci, under a NRSA scholarship.

Amanda Kay, Ph.D.

Amanda joins Deep Genomics with 19 years of experience in the pharmaceutical and biotechnology industries. She comes with expertise in driving strategy, business development, as well as commercial and financial planning, to set the course for innovative drug platforms.  

Prior to Deep Genomics, Amanda was Senior Vice President of Business Development at Synlogic, Inc., a clinical-stage company bringing the transformative potential of synthetic biology to medicine. She played a key role in defining the company’s strategy, which led to the company’s public launch and collaboration with Ginkgo, raising more than $160M in equity. While Chief Operating Officer for Pfizer’s Inflammation and Immunology Research Unit, Amanda drove strategy and investment across the early discovery and clinical portfolio, as well as enabling platforms, with several programs now in Phase 3 development. Previously, Amanda was the strategic lead on the marketing team for transplant and oncology products at Genzyme, which was acquired by Sanofi at that time. She began her business career at L.E.K. Consulting, where she led over fifty engagements, with clients ranging from startups to pharmaceutical companies.

Amanda received her Ph.D. in molecular and cellular biology from Harvard University and earned a B.S. in bacteriology at the University of Wisconsin, Madison.

Amit Deshwar, Ph.D.

Amit Deshwar is the Head of Predictive Systems at Deep Genomics.  Under his leadership, Deep Genomics has developed more than 40 machine learning models of molecular phenotype and developed novel GalNAc hepatocyte delivery technology.  Recently his team has released the AI Workbench 2.0, that fuses deep mechanistic understanding of SBO activity, predictive models and high throughput sequencing datasets that enables rapid development of expression increase SBOs.  

Prior to Deep Genomics, he worked at Google where he built a highly distributed log parsing system and power supply firmware that enabled co-ordinated reductions in peak power consumption.  In addition, he founded a startup that matches employers and potential employees using predictive models of personality and workplace attributes. 

Amit received bachelor degrees in Software Engineering and Psychology from the University of Calgary.  His Phd is from the University of Toronto, where he studied machine learning for oncology, and built tree-structured Baysesian nonparametric models for untangling the complex biology of intra-tumour heterogeneity. 

Jeffrey Brown, Ph.D.

Dr. Jeffrey Brown joined Deep Genomics as a seasoned biotech leader with extensive experience in preclinical and IND-enabling research, including a particular focus on genetically-defined disorders and antisense oligonucleotides. He has worked across multiple therapeutic areas, including neuropsychiatry, neurodegeneration, neuromuscular diseases, and metabolic diseases and has led more than 20 preclinical programs, successfully advancing a number of these into clinical development. 

Dr. Brown was most recently at Voyager Therapeutics, where he was responsible for building the research organization and leading multiple gene-therapy discovery research programs. Earlier, he was with Wave Life Sciences, where he led more than a dozen programs, several of which advanced to IND enabling studies. He also helped develop Wave's high-throughput screening capabilities and bioinformatics infrastructure. Prior to that, at Alexion, Dr. Brown was responsible for building the RNA therapeutics capabilities, including an RNA screening platform. He led a team at Alexion that successfully identified novel siRNA targets. He has held additional discovery and preclinical research roles with Bristol Myers Squibb, Pfizer, and Amgen. 

Dr. Brown earned his Ph.D. in Pharmacology and Toxicology at the University of Utah and was a postdoctoral research fellow at Harvard Medical School and then Boston University School of Medicine.

Matt Cahill, J.D., Ph.D., M.B.A.

Matt is the Head of Business Operations and Chief of Staff at Deep Genomics. He serves as a member of the leadership team and on the board of directors. As one of the founding employees, he established and scaled the finance, legal, and HR functions, and helped build out the leadership team. He plays a central role in business development, leading biopharma transactions. He also led the company’s Series A and B financings, and helped craft and operationalize the company’s strategy.

Prior to joining Deep Genomics, he spent several years as a marine microbiologist and worked in intellectual property law. 

Matt received his J.D. and MBA from the University of Toronto with an emphasis on biotechnology, entrepreneurship, and strategy. He received his Ph.D. from the University of Cambridge, where he studied the genomes of soil bacteria using novel sequencing technologies.

Hyla Pollak

Hyla Pollak is Vice President of People Operations at Deep Genomics with more than 25 years of experience in Human Resources.

Prior to Deep Genomics, Hyla was Vice President of People at Newtopia Inc., where she helped the company grow from six employees to a team of more than 150 personnel and implemented talent management strategies throughout the company’s expansion. During her tenure at Newtopia, the company earned the Great Place to Work® (GPTW) designation in 2020. Prior to this, she was partner/consultant at Gemini Consulting where she developed company training programs, was business owner of Discovery Toys, and started her career at Sony of Canada as human resources benefits administrator.

Hyla received her BA in Psychology from York University and a Post Graduate certificate in Human Resources Management and Services from Seneca College of Applied Arts and Technology.

Daniele Merico, Ph.D.

Daniele Merico is the  Head of Target Identification and interim Co-Director of Preclinical Research at Deep Genomics. Since the company started developing therapeutic oligonucleotides in 2017, he has led the identification of genetically-defined disorders targetable by splicing modulation and expression increase.

Prior to joining Deep Genomics in 2015, Daniele was the bioinformatics core facility manager at The Centre for Applied Genomics at the Hospital for Sick Children, a major pediatric research hospital in Toronto. In that capacity, he supervised 10 bioinformaticians working on academic and service projects comprising exome and whole genome sequencing, RNA-seq, ChIP-seq and de-novo genome assembly for animal, plant and microbial species. Throughout his scientific career, Daniele has authored more than 80 peer-reviewed articles in the fields of human genetics, genomics, systems biology, oncology and immunology.

Daniele received a B.Sc. in Molecular Biotechnology and a M.Sc. in Bioinformatics from the University of Milano-Bicocca (Italy), a Ph.D. in Molecular and Cellular Biology from the University of Milano (Italy) and he was a postdoctoral fellow at the University of Toronto under the supervision of Prof. Gary Bader and Prof. Andrew Emili.


Troy Simpson

Troy Simpson is the head of Research Operations at Deep Genomics. Joining the founding team as a software engineer, Troy helped design and build the infrastructure and teams that enable machine learning and experimental biology at Deep Genomics. Troy has managed strategy and operations of the platform, recently focused on the growing business development efforts at Deep Genomics, and leads external partnerships.

Prior to joining Deep Genomics, Troy was an early team member and founder of several startups, utilizing big data and cloud computing for analytics. 

Troy received his Bachelor of Honours Computer Science from the University of Waterloo in 2006.


Strategic Advisory Board

Jennifer Cook, M.B.A., M.S.

Board Member, BridgeBio; CEO, Grail; Senior Management, Genentech & Roche

Peter Barton Hutt, L.L.B., L.L.M

Senior Counsel, Covington & Burling, LLP

Steve Jurvetson, M.S.E.E., M.B.A.

Co-Founder, Future Ventures Board Member, SpaceX, Tesla

Vinod Khosla, M.S., M.B.A.

Founder, Khosla Ventures; Co-Founder, Sun Microsystems

Vern Norviel, M.S., J.D.

Partner, Wilson Sonsini Goodrich and Rosati; Adjunct Professor, UC Berkeley

Jennifer Cook, M.B.A., M.S.

Jennifer Cook, an Advisor at Deep Genomics, has had a 30-year career in Biotech and Pharmaceuticals and is currently focused on providing advisory support to senior executives in the healthcare field. She serves on the Boards of Directors of Denali Therapeutics, BridgeBio Pharma, Ambys Medicines, Gyroscope Therapeutics, and Jazz Pharmaceuticals. 

Most recently, she was the Chief Executive Officer of GRAIL, a healthcare company focused on the early detection of cancer. Previously, Jennifer was at Roche Pharmaceuticals/ Genentech where she held a number of senior management positions, covering the full life-cycle of pharmaceutical product development and commercialization. Jennifer started her career in research and early development at Genentech and a venture-backed start-up company. In 2016, Jennifer was recognized for her contributions to the healthcare industry and her inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association. 

Jennifer holds a B.A. in Human Biology and M.S. in Biology from Stanford University, as well as an M.B.A. from the Haas School of Business at University of California, Berkeley.


Peter Barton Hutt, L.L.B., L.L.M

Peter Barton Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling LLP, specializing in food and drug law for more than five decades.

From 1971 to 1975 Mr. Hutt was Chief Counsel for the U.S. Food and Drug Administration (FDA) and led the establishment of key regulations related to nutrition labeling, drug requirements, and medical devices that govern to this day. He has been a member of the National Academy of Medicine since its founding in 1971 and is a member of the board of directors of public biotechnology companies such as Moderna, Inc., Immunomedics, Inc., Flex Pharma, Inc. and Q Therapeutics, Inc., as well as a member of Boards of Directors and advisory committees of private companies. He has received numerous awards, including being named one of the 40 best healthcare attorneys in the United States by the National Law Journal.

Peter received a B.A. from Yale University, an L.L.B. from Harvard Law School and an L.L.M. from New York University School of Law. 


Steve Jurvetson, M.S.E.E., M.B.A.

Steve Jurvetson is an early-stage venture capitalist with a focus on founder-led, mission-driven companies at the cutting edge of disruptive technology and new industry formation.  Steve was the early VC investor in SpaceX, Tesla, Planet, Memphis Meats, Hotmail, D-Wave, Boring, Zoox and the deep learning companies Mythic and Nervana.  He also led founding investments in five companies that went public in successful IPOs and several others that became billion-dollar acquisitions.

Prior to co-founding Future Ventures and Draper Fisher Jurvetson, Steve was an R&D Engineer at Hewlett-Packard, where seven of his chip designs were fabricated. He also worked in product marketing at Apple and NeXT and management consulting with Bain & Company.  In 2017, Steve received the Visionary Award from SV Forum. In 2016, President Barack Obama appointed Steve as a Presidential Ambassador for Global Entrepreneurship. Steve has also been honored as one of "Tech's Best Venture Investors" by Forbes, and as the “Venture Capitalist of the Year” by Deloitte.  

Steve completed his undergraduate Electrical Engineering degree at Stanford in 2.5 years, graduating #1 in his class, and went on to earn a MSEE and MBA from Stanford.



Vinod Khosla, M.S., M.B.A.

Vinod Khosla is an entrepreneur, investor, and technology fan. He is the founder of Khosla Ventures, which is focused on impactful technology investments in software, AI, robotics, 3D printing, healthcare and more.

Mr. Khosla was a co-founder of Daisy Systems and founding CEO of Sun Microsystems where he pioneered open systems and commercial RISC processors. One of Mr. Khosla’s greatest passions is centered around mentorship by being a mentor to entrepreneurs, assisting entrepreneurs and helping them build technology-based businesses. Mr. Khosla is driven by the desire to make a positive impact through the application of technology to reinvent societal infrastructure and multiply resources. He is also passionate about Social Entrepreneurship.

Vinod holds a Bachelor of Technology in Electrical Engineering from IIT, New Delhi, a Master's in Biomedical Engineering from Carnegie Mellon University, and an MBA from the Stanford Graduate School of Business.


Vern Norviel, M.S., J.D.

Vern Norviel is a partner at Wilson Sonsini Goodrich & Rosati and a senior practitioner in the firm's patents and innovations counseling practice. Vern has three decades of experience formulating successful strategies for life science companies and helping them develop intellectual property programs. He represents a wide variety of companies as well as venture capital firms in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine. Vern's interest in the field of personalized medicine prompted him to become the first attorney to have had his or her entire genome sequenced and made available in a public database.

Before joining the Wilson Sonsini Goodrich & Rosati in 2003, Vern was the general counsel and corporate secretary of Perlegen Sciences, Inc., a start-up biotechnology company that scans the entire human genome for important therapeutic and diagnostic products. Previously, as senior vice president and general counsel, he was an early employee of Affymetrix, the biotechnology company that pioneered and developed DNA chip technology. He was also a partner at Townsend and Townsend and Crew in Palo Alto.

Vern received his J.D. with honors from the University of San Francisco School of Law, a Master’s degree from the University of Santa Clara, and an undergraduate degree with honors from the University of Colorado.

 


Scientific Advisory Board

Masad Damha, Ph.D.

Distinguished James McGill Professor of Chemistry, McGill University

Steven Dowdy, Ph.D.

Professor, University of California San Diego School of Medicine

Yann LeCun Ph.D.

Chief AI Scientist, Facebook; Professor, New York University

Benjamin Neale, Ph.D.

Associate Professor in the Analytic and Translational Genetics Unit, Massachusetts General Hospital

Masad Damha, Ph.D.

Masad Damha, an advisor at Deep Genomics, is a Distinguished James McGill Professor of Chemistry with over 35 years of experience in nucleic acid drug discovery and development.  His research group at McGill University focuses on synthesis and structural analyses of chemically modified oligonucleotides directed toward biomedical and diagnostic applications. 

His 200+ publications and dozens of patents issued have been widely cited and used in both fundamental sciences and oligonucleotide based therapeutic applications. Masad is the recipient of several awards from the Canadian Society for Chemistry, the Queen Elizabeth II Diamond Jubilee Medal (Governor General of Canada), and McGill’s Fessenden Professorship in Science Innovation. He has recently served as President of the International Society of Nucleosides, Nucleotides, Nucleic Acids, and of the Oligonucleotide Therapeutics Society.    

Masad graduated from McGill with a B.Sc. (Hons) in Chemistry (1983) and then a Ph.D. in Organic Chemistry (1988) under the mentorship of Kelvin K. Ogilvie developing methods for the chemical synthesis of RNA and its analogues. 



Steven Dowdy, Ph.D.

Steven F. Dowdy, an advisor at Deep Genomics, specializes in the development of RNA therapeutics and in oligonucleotide delivery systems. He serves as a Professor of Cellular & Molecular Medicine at University of California at San Diego School of Medicine His lab is focused on the molecular details of delivery of RNA therapeutics across the endosomal lipid bilayer and the synthesis of endosomal escape domains to overcome this rate-limiting billion year old barrier, and was the first to synthesize bioreversible, charge neutralizing phosphotriester backbone RNAi prodrug triggers that avoids kidney clearance, increases metabolic stability and enhances endosomal escape. 

Previously, Steven was a Howard Hughes Medical Institute Investigator for 18 years (1994-2012) and an Assistant Professor at Washington University School of Medicine, St. Louis (1994-2001). He first started advising biotech and pharmaceutical companies when he was a graduate student and currently sits on five SABs.  Steven is a thrice-elected member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS). 

He received his Ph.D. in Molecular Genetics from UC Irvine working on tumor suppressor genes, and performed his postdoctoral fellowship at MIT working on the biochemistry of the Rb tumor suppressor gene.


Yann LeCun Ph.D.

Yann LeCun is VP & Chief AI Scientist at Facebook and Silver Professor at NYU affiliated with the Courant Institute of Mathematical Sciences & the Center for Data Science. He was the founding Director of Facebook AI Research and of the NYU Center for Data Science. He received an Engineering Diploma from ESIEE (Paris) and a PhD from Sorbonne Université. After a postdoc in Toronto he joined AT&T Bell Labs in 1988, and AT&T Labs in 1996 as Head of Image Processing Research. He joined NYU as a professor in 2003 and Facebook in 2013. His interests include AI machine learning, computer perception, robotics and computational neuroscience. He is the recipient of the 2018 ACM Turing Award (with Geoffrey Hinton and Yoshua Bengio) for "conceptual and engineering breakthroughs that have made deep neural networks a critical component of computing", a member of the National Academy of Engineering and a Chevalier de la Légion d’Honneur.


Benjamin Neale, Ph.D.

Benjamin Neale is an associate professor in the Analytic and Translational Genetics Unit (ATGU) at Massachusetts General Hospital (MGH), where he directs the Genomics of Public Health Initiative. He is also an associate professor in medicine at Harvard Medical School, and an institute member at the Broad Institute. He co-leads the ADHD Initiative, a collaborative effort that focuses on genomic studies with the Broad Institute, is an active member of the Psychiatric Genomics Consortium (PGC) steering committee and analysis committee, and currently co-chair of the International Common Disease Alliance Maps Workgroup.In addition to many local research collaborations, Benjamin serves as advisor and analyst to international genetic research consortia on psychiatric diseases.

Benjamin has worked with many different international consortia, including the International Inflammatory Bowel Disease Genetics Consortium, GiANT and the Global Lipids Genomics Consortium. He has served as a statistical advisor to analysts in other PGC working groups including addictions, autism, cross-disorder, TS/OCD and schizophrenia groups. 

Benjamin holds a B.Sc. in genetics from the University of Chicago and Virginia Commonwealth University, and a Ph.D. in human genetics from King’s College in London, UK. Neale completed his postdoctoral training in Daly’s Laboratory at MGH. 

 


Board of Directors

Brendan Frey, Ph.D.

Founder and Chief Executive Officer

Elena Viboch

Investment Director, SoftBank Investment Advisers

Tom Hughes, Ph.D.

CEO Navitor

Adam D'Augelli

Partner, True Ventures

Dion Madsen, C.F.A.

Co-founder and Partner, Amplitude Ventures

Alex Morgan, M.D., Ph.D.

Partner, Khosla Ventures

Maryanna Saenko, M.S.

Co-founder Future Ventures

Matt Cahill, J.D., Ph.D., M.B.A.

Vice President of Business Operations & Finance

Brendan Frey, Ph.D.

Brendan Frey is an internationally acclaimed entrepreneur, engineer and scientist. He is Founder, CEO and Chief Engineer of Deep Genomics and he co-founded the Vector Institute for Artificial Intelligence. Brendan made fundamental contributions in the fields of deep learning, genomic medicine, and information technology. He co-authored over 200 papers in these areas, including over a dozen that appeared in Nature, Science and Cell and were on multiple occasions highlighted on the front covers of those magazines. His work with Geoffrey Hinton on the 'wake-sleep algorithm' helped to launch the field of deep learning (Science 1995). His work on deep learning and on factor graphs forms the foundation of thousands of products used world-wide; for example, the WiFi telecommunications standard is based on an algorithm that Brendan co-invented.

Brendan was a pioneer in developing AI systems that could accurately predict normal and pathological cell and genome biology, facilitating biomedical breakthroughs. This work led to the discovery of new biology, the founding of Deep Genomics in 2015, the first AI system for predicting pathogenic mutations and identifying therapeutic targets, and the development of new therapeutic candidates for patients with genetic disorders. 

Brendan is Professor of Engineering and Medicine at the University of Toronto and is a Fellow of the American Association for the Advancement of Science, a Fellow of the Institute of Electrical and Electronic Engineers, a Senior Fellow of the Canadian Institute for Advanced Research, and a Fellow of the Royal Society of Canada. Brendan has advised the leadership of Microsoft Research on machine learning and deep learning technology, and he was a member of its Technical Advisory Board. He has held numerous researcher and professor positions at the University of Illinois at Urbana-Champaign, Cambridge University in England, the Isaac Newton Institute for Mathematical Sciences and the University of Waterloo.

Brendan received his PhD from the University of Toronto in 1997.

Elena Viboch

Elena Viboch is an Investment Director at SoftBank Investment Advisers

(SBIA) where she focuses on investing in technology that impacts human
health. She brings over a decade of experience investing in and building
biotechnology companies.

Prior to joining SBIA, Elena held corporate development and operations
leadership roles at NanoString, Carmot Therapeutics and FLX Bio. She
previously managed a public biotechnology portfolio as an investor at
Kearny Venture Partners, and started her career in pharmaceutical
strategy consulting at Putnam Associates. Elena serves on the board of
directors for Deep Genomics, Karius and Pear Therapeutics, and served
as the board observer for Collective Health and Zymergen.

She holds an MBA from Harvard Business School where she graduated
with highest honors as a Baker Scholar, an MS in Biotechnology from
Johns Hopkins University, and a BA in Economics with honors from
Swarthmore College.

Tom Hughes, Ph.D.

Tom Hughes has more than 30 years of industry experience in the development and commercialization of pharmaceutical products. Tom has served since 2018 as CEO of Navitor Pharmaceuticals, a privately held biopharmaceutical company.  

Prior to joining Navitor, Tom served as President and Chief Scientific Officer, and earlier as CEO. During this time, he established Zafgen as a leading biotechnology company working in the area of rare and prevalent metabolic disorders and led the company through its Initial Public Offering in 2014. Prior to Zafgen, Tom held several positions at Novartis including Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research. He oversaw many drug discovery and development projects targeting major global aging-related health issues including obesity, diabetes, and heart disease. Tom currently serves as a member of the Board of Directors of miRagen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures, HotSpot Therapeutics, and FaunaBio.

Tom holds a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in zoology from Virginia Polytechnic Institute & State University, and a B.A. in biology from Franklin and Marshall College.


Adam D'Augelli

Adam is a partner at True Ventures. 

Prior to True Venture, Adam worked with True portfolio company B-Stock, an online marketplace for liquidating excess inventory, and initially joined the True Ventures team as an analyst in 2010.

Adam graduated magna cum laude from the University of Florida with a bachelor’s degree in science and a master’s degree in finance. As an undergraduate, he launched and ran an independent, donation-based record label and later created “Digital Frontiers,” a course exploring how the internet and technology are changing the global business landscape, which he taught at the University of Florida. 


Dion Madsen, C.F.A.

Dion Madsen has more than 25 years of experience working with innovative startups and major public companies and is the co-founder and Partner at Amplitude Ventures. 

Prior to this, he was Senior Managing Partner of the Healthcare Venture Fund at BDC Capital where the fund built two billion-dollar Canadian companies showcasing the potential of Canadian innovation. He started his venture career with RBC Capital Partners’ and moved to San Francisco in 2002 to expand RBCs platform, he was recruited to lead Unilever’s Corporate venture fund in the USA and founded and was managing director of Physic Ventures, a pioneering investor in consumer driven health.  Dion is a founding member of the C100 – a group of the leading Canadians in Silicon Valley.

Dion received his Bachelor of Commerce from the University of Saskatchewan and is a C.F.A. charterholder. 


Alex Morgan, M.D., Ph.D.

Alex Morgan is currently a Partner at Khosla Ventures, a Silicon Valley VC fund, a company which invests broadly in technology from seed stage funding to later stage capital investments. In this role, he has a special focus on biotechnology, healthcare, data science, and AI/ML. Alex serves on the boards of a number of Khosla Ventures portfolio companies. 

Prior to Khosla Ventures, Alex held consulting positions with DigiSight Technologies and and Personalis. As a scientist, he has published over 50 scientific publications, primarily at the intersection of computer science, biology, and healthcare, and has licensed IP to three separate companies.

Alex received his M.D. and Ph.D. in biomedical informatics from Stanford.


Maryanna Saenko, M.S.

Maryanna Saenko is a co-founder of Future Ventures, an early-stage Venture Capital firm that invests in frontier technologies across diverse industries. She has an interest in robotics, quantum computing, biotechnology, aerospace, and the future of food. 

Previously she was at Khosla Ventures, and prior to that at DFJ, where she focused on frontier technology investments. Maryanna was also an investment partner at Airbus Ventures where she led a series of venture investments strategically aligned with Airbus’ future-of-aerospace initiatives. Before Airbus, Maryanna was a consultant at Lux Research and a research engineer at Cabot Corporation.

Maryanna graduated from Carnegie Mellon University with a B.S. in BioMedical Engineering and a B.S. and M.S. in Materials Science and Engineering.


Matt Cahill, J.D., Ph.D., M.B.A.

Matt is the Head of Business Operations and Chief of Staff at Deep Genomics. He serves as a member of the leadership team and on the board of directors. As one of the founding employees, he established and scaled the finance, legal, and HR functions, and helped build out the leadership team. He plays a central role in business development, leading biopharma transactions. He also led the company’s Series A and B financings, and helped craft and operationalize the company’s strategy.

Prior to joining Deep Genomics, he spent several years as a marine microbiologist and worked in intellectual property law. 

Matt received his J.D. and MBA from the University of Toronto with an emphasis on biotechnology, entrepreneurship, and strategy. He received his Ph.D. from the University of Cambridge, where he studied the genomes of soil bacteria using novel sequencing technologies.

Investors

SBIA

fidelity

cpp

alex

true

Amp

khosla

magnetic

future


Offices

Deep Genomics has offices in Toronto and Boston. The AI platform and preclinical research teams are located in the heart of Toronto, the fastest growing tech hub in North America and widely recognized as one of the most livable cities in the world. The facilities are located in the MaRS Discovery District, right beside the University of Toronto, four research hospitals, three medical research institutes, and the AI research labs of Google, Uber and the Vector Institute for Artificial Intelligence. The clinical development and business development teams are led out of Boston.